Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss

Articles From: IMPAX LABORATORIES 96 HOUR ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Lead Plaintiff Motion Deadline in Securities Class Action Lawsuit Against Impax Laboratories, Inc. to Imperial Tobacco Buys 120,000 Own Shares For Treasury

This site contains about 74,006 documents.
View by:
Title  |  Date  |  Author  |  Collection  |  Interest  |  Popularity
Page:   1   100   200   300   400   500   600   700   800   970   980   990   1,000   1,010   1,020   1,030   1,040   1,050   1,056   1,057   1,058   1,059   1,060   1,061   1,062   1,063   1,064   1,065   1,066   1,067   1,068   1,069   1,070   1,071   1,072   1,073   1,074   1,075   1,076   1,077   1,078   1,079   1,080   1,081   1,082   1,083   1,084   1,085   1,090   1,100   1,110   1,120   1,130   1,140   1,150   1,160   1,170   1,200   1,300   1,400   1,500   1,600   1,700   1,800   1,900   2,000   2,467 

2013/5/2
IMPAX LABORATORIES 96 HOUR ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Lead Plaintiff Motion Deadline in Securities Class Action Lawsuit Against Impax Laboratories, Inc.
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
View more IMPAX LABORATORIES 96 HOUR ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Lead Plaintiff Motion Deadline in Securities Class Action Lawsuit Against Impax Laboratories, Inc. analysis
Sign-up for IMPAX LABORATORIES 96 HOUR ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Lead Plaintiff Motion Deadline in Securities Class Action Lawsuit Against Impax Laboratories, Inc. investment picks
2013/5/28
Impax Laboratories and Tangoe Set to Join S&P SmallCap 600
NEW YORK , May 28, 2013 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 index after the close of trading on Friday, May 31 : Impax Laboratories Inc. (NASD: IPXL) will replace Cymer Inc. (NASD: CYMI). ASML Holding NV is acquiring Cymer in a deal expected to be completed on or about that date pending final approvals.
View more Impax Laboratories and Tangoe Set to Join S&P SmallCap 600 analysis
Sign-up for Impax Laboratories and Tangoe Set to Join S&P SmallCap 600 investment picks
2013/6/5
Impax Laboratories Announces Reduction in Workforce
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced a reduction in its workforce as a part of the Company’s efforts to streamline its operations in response to the need to reduce expenses and adapt to changing market conditions.
View more Impax Laboratories Announces Reduction in Workforce analysis
Sign-up for Impax Laboratories Announces Reduction in Workforce investment picks
2013/5/17
Impax Laboratories Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S.
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig® (zolmitriptan) tablets and orally disintegrating tablets, 2.5 mg and 5 mg, in the U.S., as part of a Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited (AstraZeneca). Zomig® is indicated for the treatment of migraine headaches in adults.
View more Impax Laboratories Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S. analysis
Sign-up for Impax Laboratories Launches Authorized Generic of Zomig (zolmitriptan) Tablets and Orally Disintegrating Tablets in the U.S. investment picks
2013/5/1
Impax Laboratories Reports First Quarter 2013 Results
Impax Laboratories, Inc. (NASDAQ: IPXL) today reported first quarter 2013 adjusted net income of $25.3 million or $0.37 per diluted share, compared to $35.8 million or $0.53 per diluted share in the first quarter 2012.
View more Impax Laboratories Reports First Quarter 2013 Results analysis
Sign-up for Impax Laboratories Reports First Quarter 2013 Results investment picks
2013/4/3
Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2013 Financial Results
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its first quarter 2013 financial results on Wednesday, May 1, 2013, after the close of the U.S. financial markets.
View more Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2013 Financial Results analysis
Sign-up for Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2013 Financial Results investment picks
2013/3/8
Impax Laboratories Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors
Former United States Securities and Exchange Commission attorney Willie Briscoe , founder of The Briscoe Law Firm, PLLC , and the securities litigation firm of Powers Taylor, LLP announce an investigation into potential violations of federal securities laws by certain officers and directors of Impax Laboratories, Inc. (“Impax” or “Company”) (NasdaqGS: IPXL). If you are an affected investor and you want to learn more about the lawsuit or join the action, contact Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 239-4568, or via email at WBriscoe@TheBriscoeLawFirm.com , or Zachary Groover at Powers Taylor, LLP, toll free (877) 728-9607.
View more Impax Laboratories Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors analysis
Sign-up for Impax Laboratories Shareholder Alert: Briscoe Law and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors investment picks
2013/5/10
Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Bank of America Merrill Lynch Health Care Conference on Thursday, May 16, at 8:00 a.m. Pacific Standard Time.
View more Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference analysis
Sign-up for Impax Laboratories to Present at the Bank of America Merrill Lynch 2013 Health Care Conference investment picks
2013/3/1
Impax Laboratories to Present at the Cowen & Company 33rd Annual Health Care Conference
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Cowen & Company 33 rd Annual Health Care Conference on Wednesday, March 6, at 8:00 a.m. Eastern Standard Time.
View more Impax Laboratories to Present at the Cowen & Company 33rd Annual Health Care Conference analysis
Sign-up for Impax Laboratories to Present at the Cowen & Company 33rd Annual Health Care Conference investment picks
2013/5/24
Impax Laboratories to Present at the Deutsche Bank 38th Annual Health Care Conference
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Deutsche Bank 38 th Annual Health Care Conference on Thursday, May 30, at 12:00 p.m. Eastern Standard Time.
View more Impax Laboratories to Present at the Deutsche Bank 38th Annual Health Care Conference analysis
Sign-up for Impax Laboratories to Present at the Deutsche Bank 38th Annual Health Care Conference investment picks
2013/6/3
Impax Laboratories to Present at the Jefferies Global Healthcare Conference
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, at 2:30 p.m. Eastern Standard Time.
View more Impax Laboratories to Present at the Jefferies Global Healthcare Conference analysis
Sign-up for Impax Laboratories to Present at the Jefferies Global Healthcare Conference investment picks
2013/5/20
Impax Laboratories to Present at the UBS Global Healthcare Conference
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time.
View more Impax Laboratories to Present at the UBS Global Healthcare Conference analysis
Sign-up for Impax Laboratories to Present at the UBS Global Healthcare Conference investment picks
2013/3/14
Impax Laboratories, Inc. Continues to Ignore FDA Warnings, Causing a Delay in Bringing a New Drug to Market; Robbins Arroyo LLP Investigates on Behalf of Impax Shareholders
SAN DIEGO and HUNTERSVILLE, N.C. , March 14, 2013 /PRNewswire/ --  Shareholder rights firm Robbins Arroyo LLP is investigating whether officers and directors of Impax Laboratories, Inc. (NASDAQ: IPXL) breached their fiduciary duties to shareholders by failing to correct the Company's inadequate quality controls and deficiencies in its manufacturing processes.
View more Impax Laboratories, Inc. Continues to Ignore FDA Warnings, Causing a Delay in Bringing a New Drug to Market; Robbins Arroyo LLP Investigates on Behalf of Impax Shareholders analysis
Sign-up for Impax Laboratories, Inc. Continues to Ignore FDA Warnings, Causing a Delay in Bringing a New Drug to Market; Robbins Arroyo LLP Investigates on Behalf of Impax Shareholders investment picks
2013/4/29
Impax Pharmaceuticals and GlaxoSmithKline Terminate Their Collaboration on IPX066 (RYTARYTM)
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Impax and GlaxoSmithKline (GSK) are terminating their collaboration for the development and commercialization of IPX066 outside the United States (U.S.) and Taiwan.
View more Impax Pharmaceuticals and GlaxoSmithKline Terminate Their Collaboration on IPX066 (RYTARYTM) analysis
Sign-up for Impax Pharmaceuticals and GlaxoSmithKline Terminate Their Collaboration on IPX066 (RYTARYTM) investment picks
2013/3/19
Impax Pharmaceuticals Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting
Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced the presentation of results from its RYTARY TM (IPX066) Phase III and open-label extension trials at the 65 th Annual Meeting of the American Academy of Neurology in San Diego, CA on March 18, 2013.
View more Impax Pharmaceuticals Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting analysis
Sign-up for Impax Pharmaceuticals Announces Presentation of RYTARYTM (IPX066) (Carbidopa and Levodopa) Extended-Release Capsules Phase III and Open-Label Extension Data at the American Academy of Neurology 2013 Annual Meeting investment picks
2013/3/4
Impax Provides an Update on FDA Inspection of Hayward Facility
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the U.S. Food and Drug Administration (FDA) completed its re-inspection of the Company’s Hayward manufacturing facility in connection with the previously disclosed Form 483 issued in March 2012.
View more Impax Provides an Update on FDA Inspection of Hayward Facility analysis
Sign-up for Impax Provides an Update on FDA Inspection of Hayward Facility investment picks
2013/5/1
Imperial Holdings Acquires 93 Life Settlement Policies
Imperial Holdings, Inc. (NYSE: IFT) ("Imperial" or the "Company"), a specialty finance company with a focus on providing liquidity solutions to owners of illiquid financial assets, announced today it has acquired 93 polices with a total face value of approximately $340 million.
View more Imperial Holdings Acquires 93 Life Settlement Policies analysis
Sign-up for Imperial Holdings Acquires 93 Life Settlement Policies investment picks
2013/3/4
Imperial Holdings Announces Signing of Commitment Letter for $45 Million Shareholder Bridge Financing
Imperial Holdings, Inc. (NYSE:IFT) ("Imperial" or the "Company"), a specialty finance company with a focus on providing liquidity solutions to owners of illiquid financial assets, announced today it has executed a commitment letter for a $45 million bridge facility to be provided by some of the Company’s largest shareholders, including Indaba Capital Management, Nantahala Capital Management, NS Advisors and Brooklyn Capital Management, (a/k/a Bulldog Investors). Under the terms of the financing commitment, the bridge facility will have an 18 month term and will be secured against certain life settlement assets.
View more Imperial Holdings Announces Signing of Commitment Letter for $45 Million Shareholder Bridge Financing analysis
Sign-up for Imperial Holdings Announces Signing of Commitment Letter for $45 Million Shareholder Bridge Financing investment picks
2013/5/1
Imperial Holdings Secures 15-year, $300 Million Revolving Credit Facility
Imperial Holdings, Inc. (NYSE:IFT) ("Imperial" or the "Company"), a specialty finance company with a focus on providing liquidity solutions to owners of illiquid financial assets, announced today its subsidiary has executed a 15 year, $300 million revolving credit facility.
View more Imperial Holdings Secures 15-year, $300 Million Revolving Credit Facility analysis
Sign-up for Imperial Holdings Secures 15-year, $300 Million Revolving Credit Facility investment picks
2013/5/24
Imperial Holdings, Inc. Announces Annual Meeting Webcast
Imperial Holdings, Inc. (NYSE: IFT) ("Imperial" or the "Company"), a specialty finance company with a focus on providing liquidity solutions to owners of illiquid financial assets, announced today that it will webcast its Annual Meeting of Shareholders meeting on June 6, 2013.
View more Imperial Holdings, Inc. Announces Annual Meeting Webcast analysis
Sign-up for Imperial Holdings, Inc. Announces Annual Meeting Webcast investment picks
2013/5/14
Imperial Holdings, Inc. Announces First Quarter 2013 Results
Imperial Holdings, Inc. (NYSE: IFT) ("Imperial" or the "Company"), a specialty finance company with a focus on providing liquidity solutions to owners of illiquid financial assets, announced today its financial results for the quarter ended March 31, 2013.
View more Imperial Holdings, Inc. Announces First Quarter 2013 Results analysis
Sign-up for Imperial Holdings, Inc. Announces First Quarter 2013 Results investment picks
2013/3/27
Imperial Holdings, Inc. Announces Fourth Quarter and Year End 2012 Results
Imperial Holdings, Inc. (NYSE: IFT) ("Imperial" or the "Company"), a specialty finance company with a focus on providing liquidity solutions to owners of illiquid financial assets, announced today financial results for its fourth quarter and fiscal year ended December 31, 2012.
View more Imperial Holdings, Inc. Announces Fourth Quarter and Year End 2012 Results analysis
Sign-up for Imperial Holdings, Inc. Announces Fourth Quarter and Year End 2012 Results investment picks
2013/4/27
Imperial Oil Announces Start-up At Kearl Oil Sands Project
TORONTO -- Imperial Oil Ltd.
View more Imperial Oil Announces Start-up At Kearl Oil Sands Project analysis
Sign-up for Imperial Oil Announces Start-up At Kearl Oil Sands Project investment picks
2013/5/14
Imperial Reports 2013 First Quarter Financial Results
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0873990001&sourceType=1 http://media3.marketwire.com/logos/20121102-iiinew.jpg VANCOUVER, BRITISH COLUMBIA --
View more Imperial Reports 2013 First Quarter Financial Results analysis
Sign-up for Imperial Reports 2013 First Quarter Financial Results investment picks
2013/2/5
Imperial Reports on Mount Polley Exploration Results from Springer Zone
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0851530001&sourceType=1 http://media3.marketwire.com/logos/20121102-iiinew.jpg VANCOUVER, BRITISH COLUMBIA --
View more Imperial Reports on Mount Polley Exploration Results from Springer Zone analysis
Sign-up for Imperial Reports on Mount Polley Exploration Results from Springer Zone investment picks
2013/4/8
Imperial Tobacco Buys 100,000 Shares for Treasury
LONDON --
View more Imperial Tobacco Buys 100,000 Shares for Treasury analysis
Sign-up for Imperial Tobacco Buys 100,000 Shares for Treasury investment picks
2013/4/19
Imperial Tobacco Buys 100,000 Shares for Treasury at 2,257.03P
LONDON --
View more Imperial Tobacco Buys 100,000 Shares for Treasury at 2,257.03P analysis
Sign-up for Imperial Tobacco Buys 100,000 Shares for Treasury at 2,257.03P investment picks
2013/4/5
Imperial Tobacco Buys 110,000 Shares at 2,2265.62P
LONDON --
View more Imperial Tobacco Buys 110,000 Shares at 2,2265.62P analysis
Sign-up for Imperial Tobacco Buys 110,000 Shares at 2,2265.62P investment picks
2013/4/15
Imperial Tobacco Buys 110,000 Shares for Treasury
LONDON --
View more Imperial Tobacco Buys 110,000 Shares for Treasury analysis
Sign-up for Imperial Tobacco Buys 110,000 Shares for Treasury investment picks
2013/4/12
Imperial Tobacco Buys 120,000 Own Shares For Treasury
LONDON --
View more Imperial Tobacco Buys 120,000 Own Shares For Treasury analysis
Sign-up for Imperial Tobacco Buys 120,000 Own Shares For Treasury investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
Articles From: IMPAX LABORATORIES 96 HOUR ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Lead Plaintiff Motion Deadline in Securities Class Action Lawsuit Against Impax Laboratories, Inc. to Imperial Tobacco Buys 120,000 Own Shares For Treasury
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.